PATENT COOPERATION TRLATY

From the INTERNATIONAL BUREAU

	TION WE INTERNATIONAL BONEAU
PCT	To:
NOTIFICATION OF ELECTION	United States Patent and Trademark
(PCT Rule 61.2)	Office (Box PCT)
(1 01 Hale 01.2)	Crystal Plaza 2
	Washington, DC 20231 ÉTATS-UNIS D'AMÉRIQUE
Date of mailing (day/month/year)	ETATS-ONIS D'AMENIGOE
12 April 1999 (12.04.99)	in its capacity as elected Office
International application No.	Applicant's or agent's file reference
PCT/AU98/00582	
International filing date (day/month/year)	Priority date (day/month/year)
23 July 1998 (23.07.98)	24 July 1997 (24.07.97)
Applicant	
NAIR, Chenicheri, Hariharan et al	
The time of time of the time of the time of the time of time of the time of time o	
The decision and Office is beauty and find of the planting model.	
The designated Office is hereby notified of its election made	.
X in the demand filed with the International Preliminary	Examining Authority on:
24 February 19	999 (24.02.99)
in a notice effecting later election filed with the Interr	national Bureau on:
2. The election X was	
was not	
made before the expiration of 19 months from the priority	date or, where Rule 32 applies, within the time limit under
Rule 32.2(b).	
	,
The International Property of MADO	Authorized officer

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

S. Mafla

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

15

ATENT COOPERATION TRL TY

	om the INTERNATIONAL BUREAU	
PCT	То:	
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis.1 and Administrative Instructions, Section 422) Date of mailing (day/month/year)	SLATTERY, John, M. Davies Collison Cave 1 Little Collins Street Melbourne, VIC 3000 AUSTRALIE	
17 January 2000 (17.01.00)		
Applicant's or agent's file reference	IMPORTANT NOTIFICATION	
International application No. PCT/AU98/00582	International filing date (day/month/year) 23 July 1998 (23.07.98)	
The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indications appeared on record concerning: The following indication indications appeared on record concerning: The following indication indications appeared on record concerning: The following indication	the agent the common representative	
Name and Address THE AUSTRALIAN NATIONAL UNIVERSITY Canberra, ACT 2000 Australia	State of Nationality AU Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the	he following change has been recorded concerning:	
the person the name X the add	dress the nationality the residence	
Name and Address	State of Nationality State of Residence AU AU	
THE AUSTRALIAN NATIONAL UNIVERSITY Acton, ACT 2601 Australia	Telephone No.	
, tuoti and	Facsimile No.	
·	Teleprinter No.	
3. Further observations, if necessary:		
3. Turther observations, if necessary.		
4. A copy of this notification has been sent to:		
X the receiving Office	the designated Offices concerned	
the International Searching Authority	X the elected Offices concerned	
the International Preliminary Examining Authority	other:	
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer S. De Michiel	
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38	

4. 1

INTERNATIONAL SEARCH REPORT

International application No. PCT/AU 98/00582

A.	CLASSIFICATION OF SUBJECT MATTER			
Int Cl ⁶ :	A61K 51/02, 51/12 G01N 33/60, 33/84			
According to	According to International Patent Classification (IPC) or to both national classification and IPC			
В.	FIELDS SEARCHED	•		
Minimum docu IPC : A61K	umentation searched (classification system followed by cland keywords, G01N 33/- and keywords	assification symbols)		
Documentation	n searched other than minimum documentation to the exte	ent that such documents are included in t	he fields searched	
WPAT (DE	n base consulted during the international search (name of RWENT): (Carbon or Graphit:) and Fibrin: and LABSTRACTS: (Carbon or Graphit?) and (lay	d (A61K or G01N 33/-)		
C.	DOCUMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.	
X Y			11-19 1-22	
P,Y	Journal of Biomedical Materials Research, Volur 1997 (John Wiley & Sons, Inc), H. Nygren and C of Graphite and Gold with Blood", pages 130-130 whole document	C. Eriksson, "The Initial Reactions	1-22	
x	Further documents are listed in the continuation of Box C	X See patent family ar	nnex	
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means "D" document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family				
	etual completion of the international search	Date of mailing of the international sea 30/sep/1998		
AUSTRALIA PO BOX 200 WODEN AC AUSTRALIA	T 2606	Authorized officer C. C. L. C.		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 98/00582				
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
Biomaterials, Volume 8, No. 1, issued January 1987, (Butterworth & Co Ltd), E. Chigmier et al, "Haemocompatibility and Biological Course of Carbonaceous Composites for Cardiovascular Devices", pages 18-23 whole document	1-22			
Proc of the Thirty-Eighth Annual Meeting, Electron Microsc. Society Am., issued 1980, (EMSA), M.L. Rudee et al, "The interaction of Blood with Amorphous Carbon", pages 584-5				
whole document	1-22			
	DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Biomaterials, Volume 8, No. 1, issued January 1987. (Butterworth & Co Ltd), E. Chigmier et al, "Haemocompatibility and Biological Course of Carbonaceous Composites for Cardiovascular Devices", pages 18-23 whole document Proc of the Thirty-Eighth Annual Meeting, Electron Microsc. Society Am., issued 1980, (EMSA), M.L. Rudee et al, "The interaction of Blood with Amorphous Carbon", pages 584-5 whole document			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No. PCT/AU 98/00582

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Do	cument Cited in Sea Report	rch		Patent	Family Member		
wo	93/15768	AU	35068/93	EP	625055	GB	9203037
		US	5688486				

END OF ANNEX

18

REC'D 10 SEP 1999

PATENT COOPERATION TREATY

PCT

U7/4000

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2079801/AXD/ML	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).			
International application No.	International filing dat (day/month/year)				
PCT/AU 98/00582	23 July 1998		24 July 1997		
International Patent Classification (IPC	or national classification	on and IPC			
Int. Cl. ⁶ A61K 51/02, 51/12, G0	1N 33/60, 33/84				
Applicant 1. THE AUSTRALIAN NAT					
This international preliminary Authority and is transmitted t			nis International Preliminary Examining		
2. This REPORT consists of a to	tal of 4 sheets, include	ding this cover sheet			
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).					
These annexes consist of a tot	al of sheet(s).				
3. This report contains indications relating to the following items:					
I X Basis of the report					
II Priority					
III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
IV Lack of unity of invention					
Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement					
VI Certain documents cited					
VII Certain defects in the international application					
VIII Certain observations on the international application					
Date of submission of the demand 24 February 1999		Date of completion of the report 30 August 1999			
Name and mailing address of the IPEA	/AU A	Authorized Officer			
AUSTRALIAN PATENT OFFICE PO BOX 200					
WODEN ACT 2606 AUSTRALIA		STEVEN CHEW			
Facsimile No. (02) 6285 3929	Telephone No. (02) 6283 2248				

INTERNATIONAL PREISINARY EXAMINATION REPORT

International application No.

PCT/AU 98/00582

I.	Basis of the report
1.	With regard to the elements of the international application:*
	X the international application as originally filed.
	the description, pages , as originally filed, pages , filed with the demand, pages , filed with the letter of .
	the claims, pages , as originally filed, pages , as amended (together with any statement) under Article 19, pages , filed with the demand, pages , filed with the letter of .
	the drawings, pages , as originally filed, pages , filed with the demand, pages , filed with the letter of .
	the sequence listing part of the description: pages , as originally filed pages , filed with the demand pages , filed with the letter of .
2.	With regard to the language, all the elements marked above were available or furnished to this Authority in the language is which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language which is:
	the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:
	contained in the international application in written form.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority in written form.
	furnished subsequently to this Authority in computer readable form.
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
	The statement that the information recorded in computer readable form is identical to the written sequence listing hat been furnished
4.	The amendments have resulted in the cancellation of:
	the description, pages
	the claims, Nos.
	the drawings, sheets/fig
5 .	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
*	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this
**	report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

PCT/AU 98/00582

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1.	Statement		
	Novelty (N)	Claims	YES
		Claims 1-22	NO
	Inventive step (IS)	Claims	YES
	•	Claims 1-22	NO
	Industrial applicability (IA)	Claims 1-22	YES
	The opposition of the oppositi	Claims	NO

2. Citations and explanations (Rule 70.7)

Novelty (N): Claims 1-22

WO 93/15768-Document 1

Biomaterials Vol. 8(1) 1987, E. Chigmier et al-Document 2

Electron Microscopy Society of America, M.L. Rudee et al-Document 3

NEW CITATION

X, AU 48324/85 A (TETLEYMANUFACTURING PTY. LTD) 10 April 1986-Document 4 Whole document

Your independent claims 1, 2, 11 and 20 all define the reagent particles, which include a plurality of layers of carbon, as being capable of binding to fibrin. This term does not place any real limitations on the scope or ambit of the claims other than the particles must at least be suitable for that use. For example, claim 1 comprises the method steps of administering the reagent particles to a patient and detecting the presence of a detectable marker enclosed therein.

The reagent particles might be capable of binding to fibrin but the method of claim 1 does not include the step of actually binding fibrin in its scope. Claims 1, 2 and 11 would therefore be anticipated by Document 4 which discloses administering the particles of your invention to a patient to diagnose airway dysfunction.


Document 1 discloses the use of carbon allotropes and other analogous reticulate molecular structures as basic structural components for diagnostic or therapeutic agents, these are defined in claim 1. Page 5 lines 12 to 21 disclose graphite and amorphous carbon as being said carbon allotropes. Page 6 line 8 to page 7 line 6 discloses the use of said carbon allotropes in entrapping diagnostic or therapeutic entities directly or indirectly attached to the carbon skeleton. These uses are further disclosed at page 23 lines 3 to 8 and page 15 last paragraph. Therefore the subject matter of claims 1, 2, 11 and 20 is anticipated by Document 1.

Documents 2 and 3 disclose that certain types of carbon react with blood. Document 3 discloses the interaction of blood with amorphous carbon. It was found that after exposing the carbon to blood for 5 seconds a layer of native fibrinogen was deposited, 5mm thick. Document 2 discloses the deposition of fibrin onto pieces of a prepared carbon-carbon composite material of dimensions length 3mm and width 5mm (page 18 column 2 to page 19 column 2, the materials section). The deposition is disclosed in the results section page 21 column 1 lines 1 to 16.

These documents suggest that the binding of certain types of carbon to fibrin or fibrinogen is well known in the art. It would probably be common general knowledge. Reading Document 1 or 4 in light of this common general knowledge would anticipate your invention.

(Continued)

INTERNATIONAL PREMINARY EXAMINATION REPORT



PCTAU 98/00582 Supplemental Box (To be used when the space in any of the preceding boxes is not sufficient) Continuation of :V Inventive Step (IS): Claims 1-22 When the disclosure of Documents 2 and /or 3 are combined with the disclosure of Documents 1 and/or 4, as would be obvious to a person skilled in the art, all of your features of the claims are disclosed. Your claims 1-22 therefore do not involve an inventive step.